Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

DexCom, Inc. (DXCM - Analyst Report) reported a narrower loss of $6.0 million or 8 cents per share in the third quarter of the year compared with $17.3 million or 25 cents in the comparable quarter of 2012 as well as the Zacks Consensus Estimate of a loss of 13 cents.

DexCom’s total revenue surged 85.7% to $42.9 million, topping the Zacks Consensus Estimate of $36.0 million, on product revenues that more than doubled to $42.5 million from $21.1 million a year ago. Meanwhile, development grant and other revenues plunged 80.0% to $0.4 million from $2.0 million in the prior year quarter.  

Product gross profit more than tripled to $27.7 million in the quarter from $7.7 million in the third quarter of 2012. Total gross profit increased in the same magnitude to $27.6 million from $8.4 million a year ago while gross margin improved significantly to 64.3% from 36.4% in the 2012-quarter.

Product cost of sales rose 10.4% to $14.8 million from $13.4 million for the third quarter in 2012, driven by higher volume of product sales. Total cost of sales grew 4.1% to $15.3 million from $14.7 million for the third quarter of 2012.

Research and development expenses increased 14.6% to $11.8 million from $10.3 million in the third quarter of 2012. Selling, general and administrative expense soared 40.3% to $21.6 million from $15.4 million a year ago, due to additional payroll costs, share-based compensation and commissions.

DXCM had cash and cash equivalents of $33.4 million as of Sep 30, 2013, significantly up from $8.1 million as of Dec 31, 2012. Total debt remained flat at $7.0 million as of Sep 30, 2013 compared with the same as of Dec 31, 2012.

Calif.-based DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. The company relies significantly on its base of recurring revenue which reflects increasing usage rate with existing patients. Thus, higher patient base will bolster top-line for DexCom.

DXCM currently retains a Zacks Rank #3 (Hold). Currently, other medical stocks that are performing well in the medical instruments industry include Cynosure, Inc. (CYNO - Snapshot Report), CryoLife, Inc. (CRY - Snapshot Report) and Natus Medical Inc. (BABY - Snapshot Report). All of them carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%